Assignee
MIRAGEN THERAPEUTICS INC
US·15 granted patents·11 pending applications·32 citations·filing 2013–2020
Top patents by PatentIndex Score
26 records- 0190US9771585B2miR-155 inhibitors for treating cutaneous T cell lymphoma (CTCL)MIRAGEN THERAPEUTICS INC·Filed 2016·Granted Sep 26, 2017·7 cites·12 claims
- 0289US9376681B2miR-29 mimics and uses thereofMIRAGEN THERAPEUTICS INC·Filed 2015·Granted Jun 28, 2016·9 cites·12 claims
- 0387US9388408B2Oligonucleotide-based inhibitors comprising locked nucleic acid motifMIRAGEN THERAPEUTICS INC·Filed 2013·Granted Jul 12, 2016·9 cites·14 claims
- 0482US9994852B2Oligonucleotide compositions and uses thereofMIRAGEN THERAPEUTICS INC·Filed 2017·Granted Jun 12, 2018·1 cites·15 claims
- 0579US9803202B2Oligonucleotide-based inhibitors comprising locked nucleic acid motifMIRAGEN THERAPEUTICS INC·Filed 2016·Granted Oct 31, 2017·2 cites·25 claims
- 0676US9885042B2miR-92 inhibitors and uses thereofMIRAGEN THERAPEUTICS INC·Filed 2016·Granted Feb 6, 2018·2 cites·19 claims
- 0772US9994847B2miR-29 mimics and uses thereofMIRAGEN THERAPEUTICS INC·Filed 2016·Granted Jun 12, 2018·1 cites·32 claims
- 0871US2019359980A1Oligonucleotide compositions and uses thereofMIRAGEN THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 0970US10316318B2Oligonucleotide compositions and uses thereofMIRAGEN THERAPEUTICS INC·Filed 2018·Granted Jun 11, 2019·0 cites·16 claims
- 1070US9752144B2Inhibitors of MYH7B and uses thereofMIRAGEN THERAPEUTICS INC·Filed 2015·Granted Sep 5, 2017·1 cites·29 claims
- 1160US10337005B2Oligonucleotide-based inhibitors comprising locked nucleic acid motifMIRAGEN THERAPEUTICS INC·Filed 2017·Granted Jul 2, 2019·0 cites·24 claims
- 1257US10280422B2MiR-92 inhibitors and uses thereofMIRAGEN THERAPEUTICS INC·Filed 2018·Granted May 7, 2019·0 cites·42 claims
- 1357US2018127750A1Mir-155 inhibitors for treating cutaneous t cell lymphoma (ctcl)MIRAGEN THERAPEUTICS INC·Filed 2017·Application pending·0 cites
- 1454US10144930B2Inhibitors of MYH7B and uses thereofMIRAGEN THERAPEUTICS INC·Filed 2017·Granted Dec 4, 2018·0 cites·24 claims
- 1554US2019194662A1Mir-92 inhibitors and uses thereofMIRAGEN THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 1654US2019127734A1Mir-29 mimics and uses thereofMIRAGEN THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 1752US2022054528A1Treatment of adult t cell leukemia/lymphoma (atll) using mir-155 inhibitorsMIRAGEN THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 1848US2020318113A1Polynucleotide conjugates and uses thereofMIRAGEN THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 1947US10030042B2Synthesis of bicyclic nucleosidesMIRAGEN THERAPEUTICS INC·Filed 2015·Granted Jul 24, 2018·0 cites·25 claims
- 2047US9752143B2Locked nucleic acid inhibitor of miR-145 and uses thereofMIRAGEN THERAPEUTICS INC·Filed 2014·Granted Sep 5, 2017·0 cites·19 claims
- 2146US10011833B2Bridged bicyclic nucleosidesMIRAGEN THERAPEUTICS INC·Filed 2014·Granted Jul 3, 2018·0 cites·48 claims
- 2246US2020376019A1miR29 MIMICS FOR THE TREATMENT OF OCULAR FIBROSISMIRAGEN THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 2345US2020276220A1Methods for treating cutaneous t-cell lymphoma (ctcl) with mir-155 inhibitorsMIRAGEN THERAPEUTICS INC·Filed 2017·Application pending·0 cites
- 2441US2018161357A1Mir-155 inhibitors for treating amyotrophic lateral sclerosis (als)MIRAGEN THERAPEUTICS INC·Filed 2016·Application pending·0 cites
- 2536US2018080023A1Mirna mimetics and their use in treating sensory conditionsMIRAGEN THERAPEUTICS INC·Filed 2016·Application pending·0 cites
- 2636US2018250325A1Mir-19 modulators and uses thereofMIRAGEN THERAPEUTICS INC·Filed 2016·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →